Company intelligence / Profile preview
United Bio-Technology
Hengqin, Zhuhai, Guangdong, Chinatul.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
UBT251, a triple incretin receptor agonist, completed a double-blind, placebo-controlled phase 1b trial in overweight/obesity with favorable safety (mild-moderate GI AEs). The highest-dose group saw ~15% weight loss over 12 weeks. Phase 2 trial ongoing in China for obesity
- Therapeutic areas
- EndocrinologyMetabolic DisordersNephrology
- Modalities
- PeptideSmall molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Novo Nordisk (exclusive licensing agreement for UBT251 ex-China, Hong Kong, Macau, Taiwan)
Beyond the preview
Go deeper on United Bio-Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on United Bio-Technology.